Rebecka Hellsten
1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Expression of tSTAT3, pSTAT3
727
, and pSTAT3
705
in the epithelial cells of hormone-naïve prostate cancer
(
- Contribution to journal › Article
-
Mark
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
(
- Contribution to journal › Article
- 2017
-
Mark
Expression of STAT3 in Prostate Cancer Metastases
(
- Contribution to journal › Article
-
Mark
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
(
- Contribution to journal › Article
- 2016
-
Mark
N-Conjugate prodrugs of galiellalactone
(
- Contribution to journal › Article
-
Mark
Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
(
- Contribution to journal › Article
- 2015
-
Mark
Therapeutic Targeting of Nuclear Gamma-Tubulin in RB1-negative Tumors.
(
- Contribution to journal › Article
- 2014
-
Mark
Galiellalactone is a Direct Inhibitor of STAT3 in Prostate Cancer Cells.
(
- Contribution to journal › Article
-
Mark
The fungal metabolite galiellalactone interferes with the nuclear import of NF-κB and inhibits HIV-1 replication.
(
- Contribution to journal › Article